Peptide-Drug Conjugate (PDC) Development Services-Tekbiotech-Yeast and Phage Display CRO, Expert in Nano-body and Antibody Drug Development

Services

Inquiry and ordering

Name*
Phone*
Email*
Product*
Content*

Peptide-Drug Conjugate (PDC) Development Services

Peptide-drug conjugates (PDCs) have emerged as a highly promising new strategy for the development of targeted drugs due to their low molecular weight, good tissue permeability, ease of synthesis, modification, and customization, low immunogenicity, and low production costs. They are also a major research focus in the field of precision oncology and for the treatment of diseases involving “hard-to-drug” targets (e.g., PPI targets, i.e., protein-protein interaction targets) that are considered “hard-to-drug” targets. Peptide-drug conjugates (PDCs) are designed to precisely deliver highly potent cytotoxic drugs to cancer cells via targeted peptides, thereby achieving potent cancer cell killing while minimizing damage to healthy tissues.

Figure 1- Schematic diagram illustrating the mechanism of action of peptide-drug conjugates (PDCs).png

Figure 1: Schematic diagram illustrating the mechanism of action of peptide-drug conjugates (PDCs)

TekBiotech leverages its extensive experience in targeted peptide development and an integrated peptide drug development platform (including target design and synthesis, targeted peptide screening (such as phage display and in vivo animal screening), enhancement of targeted peptide affinity and stability (such as peptide affinity maturation and stapled peptide design and synthesis), PDC drug conjugate design and synthesis (linker design and optimization, selection of toxin small molecules, etc.), affinity detection, in vitro efficacy evaluation (cell binding detection, cytotoxicity detection, etc.), and in vivo efficacy evaluation (animal model experiments, in vivo imaging detection, etc.). We provide comprehensive services ranging from the design and optimization of preclinical study protocols and PDC discovery to downstream detection and efficacy evaluation, accelerating the development of drug candidates and advancing them from the laboratory to the clinical stage.

█ Peptide-Drug Conjugate (PDC) Development Services

TekBiotech offers a standardized PDC development process. Clients need only provide target information (primarily tumor-related targets and PPI targets), and TekBiotech’s scientists will design appropriate screening targets and strategies based on the targets’ characteristics to identify specific targeting peptides suitable for downstream PDC development and application. PDC development services cover a full suite of services, including the design and production of screening targets, peptide screening, enhancement of targeted peptide affinity and stability, PDC design and synthesis, affinity detection, in vitro efficacy evaluation, and in vivo efficacy evaluation in animals. To help clients optimize the efficacy and safety of the final product, the company specifically offers PDC conjugation scheme optimization services (including linker selection and design, optimization of conjugation groups or methods, and selection of small-molecule drugs/toxins), aimed at meeting the project needs of different clients. In addition, TekBiotech provides PDC design and synthesis services for cell-penetrating peptides. In addition, TekBiotech also offers PDC design and synthesis services utilizing cell-penetrating peptides (CPPs). By conferring indirect "targeting" capabilities onto CPPs, we effectively address the issue of their non-selectivity. The resulting PDCs exhibit both enhanced cell-penetrating efficiency and favorable target-tissue bias, enabling them to rapidly and efficiently reach the target site for toxin release and therapeutic action, while maintaining a relatively high safety profile.

TekBiotech primarily provides PDC development services based on cell-targeting peptides and cell-penetrating peptides:

Peptide Types

Optimization of Targeting and Stability

Linker Selection

Cell-Targeting Peptides (CTPs)

Affinity maturation;

Design and synthesis of stapled peptide;

Cleavable;

non-cleavable

Cell-Penetrating Peptides (CPPs)

Conferring indirect “targeting” (such as combining with a linker that releases in response to the microenvironment, or designing masking peptides to provide a “switch” for release, etc.);

Design and synthesis of stapled peptide;

Cleavable;

non-cleavable

█ PDC Characterization and Analysis Services

TekBiotech offers a comprehensive suite of analytical services that meet industry standards, covering all stages from early-stage screening to process scale-up. We utilize a variety of detection methods—including HPLC, mass spectrometry (MS), MALDI-TOF mass spectrometry, flow cytometry, BLI/SPR, and animal model detection—to conduct evaluations, providing critical data for process optimization.

TekBiotech offers the following characterization and analysis services:

HPLC and Mass Spectrometry (MS) Analysis	MALDI-TOF Mass Spectrometry	BLI/SPR	Flow Cytometry	Detection in Animal Models
Detect purity and molecular weight	Detect the linker, drug, and peptide are correctly linked	Analysis of targeted binding at the molecular level	Analysis of targeted binding at the cellular level	In vivo efficacy evaluation and target analysis

█ Advantages of the PDC Discovery Service Platform


One-Stop Solution	Customized PDC Solution Design	Comprehensive Characterization and Analysis Evaluation	Complementary Downstream Detection Platform
Comprehensive services ranging from scheme design, targeted peptide discovery, and PDC construction to in vivo and in vitro detection	Diverse design and synthesis of cell-targeting peptides (PDCs) and cell-penetrating peptides	Including PDC analysis at the molecular level, cellular level, and in animal models	Molecular targeting detection, cellular targeting detection, in vivo targeting detection, and efficacy evaluation